Uncategorized

Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trial

Published

2 weeks ago

on

A year after it reported a Phase 2/3 success, Compass Therapeutics on Monday revealed further results for its closely watched bispecific antibody in second-line biliary tract cancer.

In the

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version